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GENERAL COMMENTS
This manuscript is essentially the research protocol for a prospective registry on patients with intracranial atherosclerotic disease in China who were treated with intracranial angioplasty and/or stenting. The primary endpoint was target vessel stroke, hemorrhage, or death within 30 days after stenting, and the secondary endpoint was the incidence of recurrent ischemic stroke from 30 days to 1 year. The investigators aimed to demonstrate that endovascular interventional procedures (intracranial angioplasty and stenting), when performed on carefully selected patients and by experienced operators, can be safe and effective means for treating severe symptomatic ICAD refractory to medical therapy.
The prospective registry, with careful independent monitoring, is a very worthwhile effort to study procedure-relative safety and efficacy. The concerns voiced by the investigators regarding the results of SAMMPRIS study are valid, and further studies such as this prospective registry should be encouraged. The manuscript is overall well written and should be considered for publication. It can be improved by the following modifications: 1. The format of the paper should be more streamlined and better organized. The inclusion/exclusion criteria and variables of statistical analyses should best be presented in separate tables and described in the methods section. The "limitation and strength" part of the manuscript should be included in the discussion section. 2. The first sentence of the "method/design" section should be clarified. What do the authors mean by "approved by human rights committee"? 3. The authors described 3 different scenarios for treatments: the Apollo balloon-mounted stent, the Gateway balloon/Wingspan stent, and angioplasty only. It would be very useful for readers to
